GeneOne Life Science Inc (011000) — Cash Flow-to-Debt Ratio
GeneOne Life Science Inc (011000) has a Cash Flow-to-Debt Ratio of -0.04x as of March 2026, meaning its operating cash flow of ₩-2.84 Billion could theoretically repay 0% of its total liabilities (₩80.13 Billion) in one year. See 011000 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GeneOne Life Science Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for GeneOne Life Science Inc across 13 annual periods. For the full cash flow conversion analysis, see 011000 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for GeneOne Life Science Inc (2013–2025)
Year-by-year debt coverage analysis for GeneOne Life Science Inc. Check 011000 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | ₩-16.54 Billion | ₩78.31 Billion | ▲ +13.5% |
| 2024 | -0.24x | ₩-16.06 Billion | ₩65.73 Billion | ▲ +55.6% |
| 2023 | -0.55x | ₩-21.74 Billion | ₩39.52 Billion | ▲ +5.5% |
| 2022 | -0.58x | ₩-24.11 Billion | ₩41.40 Billion | ▼ -429.0% |
| 2021 | -0.11x | ₩-4.85 Billion | ₩44.04 Billion | ▲ +73.7% |
| 2020 | -0.42x | ₩-15.92 Billion | ₩38.06 Billion | ▼ -792.0% |
| 2019 | -0.05x | ₩-1.27 Billion | ₩27.09 Billion | ▲ +87.2% |
| 2018 | -0.37x | ₩-7.27 Billion | ₩19.89 Billion | ▲ +17.7% |
| 2017 | -0.44x | ₩-4.04 Billion | ₩9.09 Billion | ▼ -6.9% |
| 2016 | -0.42x | ₩-12.39 Billion | ₩29.81 Billion | ▼ -540.5% |
| 2015 | 0.09x | ₩778.50 Million | ₩8.25 Billion | ▲ +113.7% |
| 2014 | -0.69x | ₩-4.16 Billion | ₩6.03 Billion | ▼ -138.1% |
| 2013 | -0.29x | ₩-2.35 Billion | ₩8.11 Billion | — |